Ionis and AstraZeneca to develop and commercialize eplontersen

- Collaboration expected to enable faster and deeper market penetration into growing global TTR amyloidosis market - The companies will jointly develop and commercialize eplontersen in the U.S., AstraZeneca has exclusive rights to commercialize in rest of the world - Bolsters Ionis' commercial organization as it prepares for multiple product launches - Ionis to hold webcast Dec. 7, 2021, at 10 a.m. Eastern Time CARLSBAD, Calif., Dec. 7, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced it has entered into a strategic collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis' investigational antisense medicine for the treatment of transthyretin amyloidosis (ATTR).

The release as fetched from its publisher. ionis.com ↗